Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

President Trump and FDA commissioner Stephen Hahn. Photo: Pete Marovich/Getty Images

The Food and Drug Administration plans to toughen the requirements for a coronavirus vaccine emergency authorization, which would make it more difficult for one to be ready by the election, the Washington Post reported Tuesday.

Why it matters: Public skepticism of an eventual vaccine keeps increasing as President Trump keeps making promises that are at odds with members of his own administration.

  • This skepticism is bad. A rushed, unproven vaccine would be even worse.

Driving the news: The new FDA guidance would be much more rigorous than what was used to provide emergency authorization to hydroxychloroquine or convalescent plasma. Both authorizations were controversial.

  • The agency is expected to ask vaccine manufacturers to monitor late-stage clinical trial participants for a median of at least two months, beginning after the participants receive their second shot.
  • It will also be looking for at least five severe coronavirus cases in each trial's placebo group, along with cases in older people, to further indicate that the vaccine works.

Between the lines: The new standards, combined with other elements of the authorization process, would make it very unlikely than any vaccine will be ready for administration before Nov. 3.

The other side: Some critics say that an emergency authorization — versus a full approval — shouldn't be used at all for a vaccine.

  • "Things are so revved up right now that there is quite a possibility that the American public won't accept a vaccine because of all the things that are going on," Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, told the Post.

What they're saying: "The FDA has previously noted that the agency intends to issue additional guidance shortly to provide sponsors of requests for Emergency Use Authorization for COVID-19 vaccines with recommendations regarding the data and information needed to support the issuance of an EUA," the agency said in a statement.

Go deeper

Jan 14, 2021 - Health

Coronavirus deaths climbing while country deals with political unrest

Expand chart
Data: The COVID Tracking Project; Map: Andrew Witherspoon/Axios

Coronavirus deaths continue to reach tragic heights while the country grapples with a vaccine rollout, an impeachment and ongoing civil unrest.

Jan 14, 2021 - Health

WHO team arrives in China to investigate pandemic origins

Health workers at a cordoned-off section of the international airport in Wuhan, China, as the World Health Organization team arrives on Thursday. Photo: Nicolas Asfouri/AFP via Getty Images

A World Health Organization team of researchers arrived in Wuhan, China, Thursday ahead of their investigation into the origins of the COVID-19 pandemic.

Driving the news: Dominic Dwyer, a Sydney virologist based who's among the scientists on the visit, told the Australian Broadcasting Corporation they don't expect to find a "patient zero." "But we may have a much better indication of whether the virus truly started in Wuhan," he said.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!